Participants were randomly assigned by web-based permuted block randomisation ( block size 4 ) in a 1:1:1:1 ratio to the four treatment groups : cisplatin ( 50 mg/m ( 2 ) intravenously on day 1 or 2 of the treatment cycle ) and paclitaxel ( 135 mg/m ( 2 ) intravenously over 24 h or 175 mg/m ( 2 ) intravenously over 3 h on day 1 ) , with or without bevacizumab ( 15 mg/kg intravenously on day 1 or 2 ) , or paclitaxel ( 175 mg/m ( 2 ) over 3 h on day 1 ) and topotecan ( 075 mg/m ( 2 ) for 30 min on days 1-3 ) with or without bevacizumab ( 15 mg/kg intravenously on day 1 ) .